Poland Fines Pharmaceutical Wholesalers $235 Million Over Decade-Long Information Exchange
Key Takeaways
- More Than $235 Million in Fines: UOKiK imposed approximately $235.2 million (PLN 904.97 million) in penalties on four pharmaceutical wholesalers for participating in a prohibited information-sharing agreement.
- Sensitive Data Was Shared: Wholesalers exchanged nonpublic information on medicine prices, pharmacy purchases and commercial terms, allowing them to see what competitors were offering individual pharmacies.
- Competition Was Weakened: UOKiK found that the information reduced competitive uncertainty and helped participants avoid aggressive price competition, including what employees described as a “price war.”
- Major Players Were Involved: The Neuca, Farmacol and Polska Grupa Farmaceutyczna groups together accounted for more than 70% of Poland’s wholesale medicines market between 2015 and 2022.
- Leniency Spared One Company: Polska Grupa Farmaceutyczna avoided a financial penalty after applying for leniency, providing evidence and cooperating with UOKiK. The decision remains subject to appeal.
Deep Dive
For more than a decade, companies controlling much of Poland’s wholesale medicines market exchanged sensitive commercial information that showed what individual pharmacies were buying from rival suppliers, how much they were paying and what terms they had been offered, according to Poland’s Office of Competition and Consumer Protection, or UOKiK.
That knowledge took something important out of the market: uncertainty. A wholesaler considering whether to cut a price no longer had to wonder how low a competitor had gone. It could know when a small reduction would be enough to win the business, when no reduction was necessary and, in some cases, when there was room to raise the price.
UOKiK concluded that the arrangement restricted competition and imposed fines totaling approximately $235.2 million (PLN 904.97 million) on four companies. The penalties are among the more consequential competition enforcement actions in a market where the effects do not stop with the businesses buying and selling the product. Pharmacies sit between wholesalers and patients. When their suppliers compete less aggressively, UOKiK’s case is that the consequences can eventually reach the pharmacy counter.
The companies involved were hardly marginal players. The Neuca, Farmacol and Polska Grupa Farmaceutyczna groups together held more than 70% of Poland’s wholesale medicines market between 2015 and 2022. Their size meant the terms on which they competed with one another mattered across the pharmacy market.
The arrangement did not depend on publicly advertised prices. UOKiK drew that line carefully. Businesses are allowed to watch competitors and respond to prices that anyone can see. What happened here, according to the authority, was different.
The wholesalers obtained nonpublic purchasing information through IT tools connected to partner programs they operated for pharmacies. In exchange for benefits that included discounts, training and marketing support, wholesalers gained access to data about pharmacy purchases. That data could reveal purchases from competing wholesalers, including the prices and commercial terms attached to them.
Neuca and Polska Grupa Farmaceutyczna had been using the tools since October 2015. Companies from the Farmacol group joined in January 2017. With information flowing from thousands of pharmacies, the participants could build a remarkably detailed picture of what their competitors were doing. A wholesaler did not simply know that another company was discounting a medicine somewhere in the market. It could know what a particular pharmacy had bought from a competitor and the terms on which the sale had been made.
That is where market intelligence became something else in UOKiK’s account of the case. The information was shared among participants and used in their commercial decisions, allowing them to respond to competitors without the ordinary risk of bidding too aggressively for business.
If a rival was charging more for a medicine, a wholesaler could raise its own price with less fear that the pharmacy would walk away. If the rival lowered its price, the wholesaler could make a corresponding adjustment rather than go further and start a fight over the customer. Employees at one of the wholesalers supplied an unusually plain description of what they were trying to prevent: “a price war.” For pharmacies, a price war might have been rather useful.
UOKiK found that the exchange helped the companies preserve the existing balance between them, protecting margins and reducing the pressure to offer pharmacies better prices, discounts or other commercial terms. It also limited the room for other wholesalers to compete effectively against companies that supplied much of the Polish pharmacy market.
Tomasz Chróstny, president of UOKiK, said the companies had effectively “synchronised” their price lists. The authority’s position is that pharmacies lost out as competition weakened and that patients ultimately bore the cost through higher medicine prices.
The penalties reflect the scale UOKiK attached to the conduct. Neuca received by far the largest individual fine at approximately $129.7 million (PLN 499.04 million). Farmacol-Logistyka was fined approximately $104.1 million (PLN 400.53 million), while Farmacol received a penalty of approximately $906,800 (PLN 3.49 million) and Świat Zdrowia approximately $496,800 (PLN 1.91 million). Polish competition law allows a fine of up to 10% of an undertaking’s annual turnover for participation in an agreement restricting competition.
One participant, however, paid nothing. Polska Grupa Farmaceutyczna applied for leniency, provided evidence to UOKiK and cooperated during the proceedings. The company avoided a financial penalty entirely. Chróstny said its cooperation helped the authority detect and break up the arrangement, making the case a particularly expensive demonstration of the advantage that can come from being the participant that approaches the regulator first.
The European Commission also gave a favorable opinion on the decision, according to UOKiK, confirming the authority’s legal assessment of the practice and its reasoning in light of the evidence gathered during searches.
The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.



